On December 4, 2024, Peter Farrell, Director at ResMed Inc (RMD, Financial), sold 2,000 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 81,218 shares of the company.
ResMed Inc (RMD) is a global leader in the development, manufacturing, and distribution of medical equipment for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company provides cloud-connected devices and comprehensive software solutions to improve patient outcomes and reduce healthcare costs.
Over the past year, Peter Farrell has sold a total of 31,535 shares and has not purchased any shares. The insider transaction history for ResMed Inc shows that there have been 0 insider buys and 34 insider sells over the same timeframe.
On the day of the recent sale, shares of ResMed Inc were trading at $245.65, giving the stock a market cap of $35,144.37 million. The company's price-earnings ratio stands at 31.71, which is higher than the industry median of 29.58 but lower than the company’s historical median price-earnings ratio.
With a trading price of $245.65 and a GF Value of $270.16, ResMed Inc has a price-to-GF-Value ratio of 0.91, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
